- Abstract:
-
Tumors use Indoleamine 2,3-dioxygenase-1 (IDO1) as a major mechanism to induce an immunosuppressive microenvironment. IDO1 expression is upregulated in many cancers and considered to be a resistance mechanism to immune checkpoint therapies. IDO1 is induced in response to inflammatory stimuli such as IFN and promotes immune tolerance by depleting tryptophan and producing tryptophan catabolites including kynurenine in the tumor microenvironment. This leads to effector T-cell anergy and enhance...
Expand abstract - Publication status:
- Published
- Peer review status:
- Peer reviewed
- Version:
- Accepted Manuscript
- Publisher:
- American Association for Cancer Research Publisher's website
- Journal:
- Molecular cancer therapeutics Journal website
- Volume:
- 17
- Issue:
- 12
- Pages:
- 2530-2542
- Publication date:
- 2018-09-19
- Acceptance date:
- 2018-09-12
- DOI:
- ISSN:
-
1538-8514 and 1535-7163
- Pubs id:
-
pubs:921624
- URN:
-
uri:0d4fbf62-5a29-4242-9a49-40407c657439
- UUID:
-
uuid:0d4fbf62-5a29-4242-9a49-40407c657439
- Local pid:
- pubs:921624
- Language:
- English
- Keywords:
- Copyright holder:
- American Association for Cancer Research
- Copyright date:
- 2018
- Notes:
- ©2018, American Association for Cancer Research. This is the accepted manuscript version of the article. The final version is available online from American Association for Cancer Research at: 10.1158/1535-7163.mct-17-1104
Journal article
Characterization of the selective indoleamine 2,3-dioxygenase-1 (IDO1) catalytic inhibitor EOS200271/PF-06840003 supports IDO1 as a critical resistance mechanism to PD-(L)1 blockade therapy
Actions
Authors
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record